![GU Oncology Now](/img/default-banner.jpg)
- 552
- 85 289
GU Oncology Now
United States
Приєднався 5 сер 2022
GU Oncology Now delivers the latest news in therapeutics, clinical trials, conference coverage, and more, highlighting important advancements in genitourinary oncology treatments and technologies with the goal of better informing oncology decisions and improving patient outcomes.
Gene Mutations as Predictive Biomarkers for Cisplatin-Based Chemotherapy Response in Bladder Cancer
Elizabeth Plimack, MD, MS, FASCO, the Deputy Director of Fox Chase Cancer Center, provides an update on the SWOG S1314 trial for muscle-invasive bladder cancer.
She highlights the four genes that were found to be predictive of pT0 disease after neoadjuvant chemotherapy, and how a biomarker test for these genes may impact patient care and disease management moving forward.
She highlights the four genes that were found to be predictive of pT0 disease after neoadjuvant chemotherapy, and how a biomarker test for these genes may impact patient care and disease management moving forward.
Переглядів: 8
Відео
Impact of Disease Site on Germline Variants in Urinary Tract Cancer
Переглядів 36День тому
Sumati Gupta, MD, and Wendy Kohlmann, MS, continue their discussion with a focus on the difference in prevalence of pathogenic variants between patients with primary disease sites in the urethra, upper tract, and bladder.
Evaluation of Clinically Actionable Germline Pathogenic Variants in UTUC
Переглядів 6День тому
Sumati Gupta, MD, and Wendy Kohlmann, MS, discuss how certain cancer sites, like the urethra and upper tract, have a higher prevalence of pathogenic variants, as well as why comprehensive germline testing is crucial for accurate diagnosis and treatment.
Drs. Karine Tawagi and Samantha Armstrong Preview ESMO 2024
Переглядів 128День тому
The Two Onc Docs, Drs. Samantha Armstrong and Karine Tawagi, provide a brief overview of the sessions and data to look out for at the ESMO Congress 2024. The latter leads the former through the urothelial carcinoma, renal cell carcinoma, and prostate cancer presentations of note, as well as the interviews she plans to host for GU Oncology Now while at the meeting.
AUC3: Defining Gray Areas of Bladder and Kidney Cancer
Переглядів 72День тому
Rana McKay, MD, and Jonathan E. Rosenberg, MD, preview #AUC3, where experts will be parsing out and driving consensus on the gray areas in the advanced urologic cancer space.
Uromigos Live & Unplugged 2024 is almost here!
Переглядів 34День тому
Uromigos Live & Unplugged is almost here! Stay tuned for more updates by following The Uromigos on X (x.com/uromigos) and visiting Uromigos Live 2024 at GU Oncology Now (guoncologynow.com/conference/the-uromigos-live-unplugged-2024), where sessions will be livestreamed starting at 2 PM ET on Friday, September 27. Live stream schedule (all times in EDT): 9/27: 2:00pm: Perioperative Therapy in Ur...
ESMO 2024 Kidney Preview: TiNivo-2, SUNNIFORECAST, CheckMate 9ER, and More
Переглядів 1332 дні тому
In anticipation for the 2024 ESMO Congress, Katy Beckermann, MD, PhD, of Vanderbilt-Ingram Cancer Center, previews various clinical trials and studies to be presented, including those on immunotherapy for metastatic kidney cancer, HIF inhibition, treatments for non-clear cell kidney cancer, and novel biomarkers for predicting treatment responses.
Impact of Baseline Bone Pain on Survival Outcomes in Patients with MHSPC
Переглядів 10414 днів тому
Georges Gebrael, MD, discusses the results of his recent study on the impact of baseline bone pain on survival outcomes in patients with metastatic hormone-sensitive prostate cancer.
Alternative Intravesical Therapy and Patient Preferences in NMIBC
Переглядів 7914 днів тому
Sia Daneshmand, MD, of University of Southern California, shares his thoughts on alternative intravesical therapies showing the most promise in NMIBC and how they compare in terms of efficacy and safety. He also comments on how he envisions the integration of patient preferences and QOL considerations into the regular management NMIBC, particularly with regard to bladder preservation and altern...
CLARIFY: Phase 3 Diagnostic Trial of 64Cu-SAR-bisPSMA PET Imaging in Prostate Cancer Before Surgery
Переглядів 23814 днів тому
Brian Helfand, MD, PhD, of NorthShore University Health System, discusses the latest advancements in prostate cancer imaging, highlighting the challenges of traditional imaging methods and how PSMA PET CT is revolutionizing detection and treatment planning. Dr. Helfand also explores the potential of Clarity's 64Cu-SAR-bisPSMA agent and its unique benefits. Get more expert insights on prostate c...
Merging Clinical Trials With the Clinic: Bladder Cancer Therapeutic Advances With Dr. Brad McGregor
Переглядів 7021 день тому
Brad McGregor, MD, is the Director of Clinical Research for the Lank Center of Genitourinary Oncology serving as a Medical Oncologist specializing in genitourinary malignancies at the Dana-Farber Cancer Institute. His work has contributed to significant advancements in the field, including his involvement in the pivotal EV-201 trial, which led to the FDA approval of enfortumab vedotin for metas...
Perioperative Therapy, ctDNA for Advanced Bladder Cancer
Переглядів 7028 днів тому
Guru Sonpavde, MD, of AdventHealth Cancer Institute, shares his general thoughts on first-line perioperative PD-1 therapy for advanced bladder cancer, including how trials like CheckMate 274, AMBASSADOR, and NIAGRA are shaping the management approach. He also comments on research initiatives to better optimize ctDNA use in the patient care continuum.
Bladder Preservation, Biomarkers for Detection, and BCG Predictors of Response in NMIBC
Переглядів 20728 днів тому
Sia Daneshmand, MD, of University of Southern California, highlights latest advancements in bladder preservation strategies for patients with NMIBC, including how they compare to traditional approaches; some of the most promising biomarkers currently being researched for the early detection of NMIBC, and how these biomarkers might change the landscape of bladder cancer screening; and the key pr...
NCCN Guidelines Update: Impact of Ipilimumab and Nivolumab as Preferred Regimen for ccRCC
Переглядів 149Місяць тому
David Braun, MD, PhD, of the Yale School of Medicine, shares insights on the recent updates to the NCCN guidelines, focusing on the inclusion of ipilimumab and nivolumab as a preferred regimen for favorable-risk clear cell renal cell carcinoma (ccRCC). Dr. Braun provides an in-depth analysis of the long-term data from the CheckMate-214 trial, highlighting how this shift in treatment protocols c...
Staging Intermediate- and High-risk Prostate Cancer With 18F PSMA/PET/CT vs MRI
Переглядів 424Місяць тому
Staging Intermediate- and High-risk Prostate Cancer With 18F PSMA/PET/CT vs MRI
The Uromigos: Live & Unplugged 2024 in Nashville, Tennessee
Переглядів 135Місяць тому
The Uromigos: Live & Unplugged 2024 in Nashville, Tennessee
EVITA Criteria: Opening Doors for Novel Therapies in EV/Pembro-Ineligible Patients
Переглядів 102Місяць тому
EVITA Criteria: Opening Doors for Novel Therapies in EV/Pembro-Ineligible Patients
EVITA Criteria to Identify Patients Unfit for EV/Pembro
Переглядів 142Місяць тому
EVITA Criteria to Identify Patients Unfit for EV/Pembro
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
Переглядів 38Місяць тому
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
Targeting ACSS2 to Regulate HIF-2α Stability and Suppress ccRCC Growth
Переглядів 68Місяць тому
Targeting ACSS2 to Regulate HIF-2α Stability and Suppress ccRCC Growth
Future Directions in nccRCC: SAMETA, FORTUNE, and Second-Line Treatment
Переглядів 48Місяць тому
Future Directions in nccRCC: SAMETA, FORTUNE, and Second-Line Treatment
Adjuvant Setting, Toxicity Considerations for Single-Agent, Combination nccRCC Therapy
Переглядів 63Місяць тому
Adjuvant Setting, Toxicity Considerations for Single-Agent, Combination nccRCC Therapy
Management Round-Up: Translocation, Chromophobe, RMC, and Other Subtypes
Переглядів 99Місяць тому
Management Round-Up: Translocation, Chromophobe, RMC, and Other Subtypes
Evolution of Combination Therapy in nccRCC, Papillary Subtype
Переглядів 101Місяць тому
Evolution of Combination Therapy in nccRCC, Papillary Subtype
Managing Metastatic nccRCC: Historical Approaches and Current Changes
Переглядів 69Місяць тому
Managing Metastatic nccRCC: Historical Approaches and Current Changes
Defining and Prognosticating nccRCC: Constant Molecular Evolution
Переглядів 74Місяць тому
Defining and Prognosticating nccRCC: Constant Molecular Evolution
15-Gene Signature for Predicting Clear Cell Renal Cell Carcinoma Risk
Переглядів 562 місяці тому
15-Gene Signature for Predicting Clear Cell Renal Cell Carcinoma Risk
Efficacy and Toxicity of 177Lu-PSMA-617 for mCRPC in a Real-World Setting
Переглядів 1502 місяці тому
Efficacy and Toxicity of 177Lu-PSMA-617 for mCRPC in a Real-World Setting
Sequential Endoluminal Chemotherapy for Non-Invasive High-Grade UTUC
Переглядів 672 місяці тому
Sequential Endoluminal Chemotherapy for Non-Invasive High-Grade UTUC
Now he just needs to stop milking the company and to become profitable
3 month????? I think it's 3 wks.
Congratulations Vishnu!! Very proud of you.
Can we get this in Australia. Clinical trials?
Great discussion!
How significant was the non-recurrence rate increase by adding Anktiva to BCG?
I don’t trust her…
$ibrx to the moon
Grea 2:05 t news .. therapies will be available in Canada in about 20 years😅
It’s funny because immunotherapy is a farce! There has been many purposed reasons and cures for the emperor of all maladies but the FDA goes after the real men and woman who have cured this disease!
This is incredible news! Thanks for sharing this information about PSS and Anktiva.
Wow.
Very helpful. I don’t know if you’re responding to these but I found I had Stage 1A. Tumor less than 4cm (3.7) with RTI but nothing else. I am trying to decide between carboplatin or going surveillance. The way it’s been communicated to me is that I could go from 80% cured to 95%+ cured. I know you can’t say for definite one way or the other but I’d rather not have chemotherapy if I don’t need it but should I have it if I can increase the cure rate?
Od czasów złowrogiego kowida na dźwięk słowa "ekspert" dostaje odruchu wymiotnego. Ciekawe dlaczego?!
Can Relugolix be combined with Abiraterone?
Si può sapere il punteggio Gleason dei pazienti arruolati nel studio embark? Grazie
P r o m o S M 🙄
Thank you for this video.
Great info. Please do updates.
Would the findings of the MIRAGE random trial still prevail , if BOTH the MRI-guided AND CT-guided radiation were delivered in the LOW-dosage/20-sessions scheme ?? I am about to undergo radiation treatment for Gleason 7 (3+4) with a CT-guided machine in the LOW dosage/20-sessions scheme and wondering if I should postpone it until access to a MRI-guided machine is feasible. Any comments will be much appreciated
Wondering if ever, there will be studies on Ivermectin, Genestein, Apigenin, Curcumin, Oleurpein, IP6 and so forth. (standard is good, Liposomal is better)
I am 54yrs of age, found I have stage 4 rcc in August....have been seeing good results with tkio's....massnated cancer in lungs is gone and tumor shrunk 10%.....
Thanks 👍
You might want to investigate the SeCUre Trial. The results are stunning.
In a nutshell, what did the trial show?
@@wilander1 Am I allowed to answer?
@@wilander1 Can't answer, find my SS
@@DCGreenZone what's your "ss"?
@@wilander1 eeeeee mayle meeeeeee at Geeeeeeeee Mayle
Hi dear, I was impressed by the quality of your videos on your UA-cam channel. The content is top-notch, and the thumbnails are visually appealing. However, I noticed that your SEO could use some improvement. If you optimize your videos for search engines, you'll see a significant increase in viewership. I'd be glad to assist you in this process if you're open to it.
Nice video 😮😮😮
What about SBRT leading to a secondary cancer?
Thanks Dr Deeks !! waited 11 years to hear this. I will investigate futrher ,thank you. Dan dx St4 psa was 72 6 w/ 6mets. 11 years ;later on Zytiga undetectabel for[past 9 years. Gong to City of Hope. now
Thank you for sharing. Concise and informative.
Dr. Kishan said they would be able to announce whether there were any findings about any difference in erectile dysfunction towards the end of 2023, as by then the two year mark will be reached. Are there any findings yet? I am scheduled to do Mridian SBRT in late November, and would love to have good news showing that it will lead to reduced risk of ED before I undergo this treatment.
Was hoping the same. Any updates would be much appreciated.
@@wilander1 Getting ready to start radiation..have the choice of MRI Linac or Proton..sigh..would be nice to have that data now
@@dmcarden After much research, my understanding is that the MRI Linac is the most advanced and targeted technique. Good luck!
Not sure if i am I understanding this panel correctly. I was recently diagnosed with a 53mm RCC and my Urologist wants to perform a Radical Nephrectomy. I am in no pain but only occasional hematuria. If I understand this panel, I should be introduced to immunotherapy for up to 12 weeks and reevaluate then vs running into surgery.
Good stuff
Forced me to watch. Hope it helps. If I make it thru
My husband has been diagnosed with stage 4 kidney cancer. We think this means it has metastasized to 3 lymph nodes near the kidney and now there is a spot on his brain that is 15 mm. He will be getting radiation for the brain spot. Where should he go for the best treatment?
*Promo SM* 😂
What is a top treat protocol for a man of 76 years who is ineligible for chemo and radiation due to history?
Thank you! It Brings much hope for our family
good job anna 👏👏👏
Very proud of you Rohan.All the best always 👍
Dr. Rohan very Insightful!! Thanks for sharing!! 😊
Proud of u Rohan 🙏👍😘😘
Superb meaningful
Promo_SM
I SUFFERED FROM TMAU FOR 6 YEAR'S, FINALLY GOT CURED WITH ALTERNATIVE HERBAL HEALING AND BODY CLEANSER ON UA-cam, DOCTOR OKOUROMI TREATMENT WORK'S PERFECTLY WELL,,,,,,,,,,,,,,,,,,,,,,,,
I SUFFERED FROM TMAU FOR 6 YEAR'S, FINALLY GOT CURED WITH ALTERNATIVE HERBAL HEALING AND BODY CLEANSER ON UA-cam, DOCTOR OKOUROMI TREATMENT WORK'S PERFECTLY WELL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,